FIELD: medicine.
SUBSTANCE: present invention relates to a long-term absorbable subcutaneous polymer implant with a controlled release of 0.09 mg of a preparation per day of a pre-concentrated pharmacologically active substance for the treatment of endometriosis characterized by the fact that the biodegradable implant contains from 5 to 19 or from 21 to 200 mg of gestrinone in the form of particles, homogeneously dispersed in a biodegradable and bio-absorbable polymer matrix, wherein the polymer matrix contains from 1% to 20% of a biodegradable polymer with respect to weight, so that it has a coating with thickness of 0.1 mm to 0.7 mm, formed by a bioabsorbable polymer membrane, wherein said membrane consists of a polylactic-co-glycolic membrane acid (PLGA) and copolymers of D, L-lactic acid, and in that it has a cylindrical shape in the form of a rod with straight and or rounded ends, with length of 2 and 20 mm and diameter of 1 to 6 mm.
EFFECT: present invention provides the development of an implant, which for a long period of 4.5 to 6 months allows maintaining the required concentration of the drug in the body, providing effective treatment of endometriosis, and also provides avoiding toxicity peaks and therapeutic fluctuations and minimizing other undesirable effects.
4 cl, 5 dwg
